Our corporate headquarters is located at 5627 Oberlin Drive, Suite 120, San Diego, CA 92121.
We were incorporated in Delaware in 2019 under the name Entos, Inc. and changed our name to Iambic Therapeutics, Inc. in 2023.
We became a publicly traded company on October 14, 2026, and our common stock began trading on the Nasdaq Global Select Market on October 15, 2026.
Our fiscal year end is December 31.
Our common stock trades on the Nasdaq Global Select Market under the symbol “IAM”.
Our transfer agent is Computershare Trust Company, N.A.
Please contact our transfer agent Computershare Trust Company, N.A.
Computershare Trust Company, N.A.
150 Royall Street
Canton, Massachusetts 02021
(800) 962-4284
(781) 575-3100
Quarterly and annual reports, as well as other SEC filings, can be accessed in the Financial Information section of our Investor Relations website or directly from the SEC at www.sec.gov.
Our independent auditor is Deloitte & Touche LLP.
Please email investor@iambic.ai
